The global biological therapies market for cancer is expected to grow from $157 billion in 2025 and is projected to reach $225 billion by the end of 2030, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025 to 2030.
The biological therapies for cancer market has experienced rapid growth, driven by increasing adoption of targeted and immuno-oncology therapies across multiple tumor types. Rising demand for precision medicine is a key growth factor, as clinicians and healthcare systems prioritize treatments tailored to the molecular and immunological profile of individual patients. Advances in monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) are expanding the range of effective treatment options and enabling more durable clinical responses.
Major global players, including Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, AstraZeneca, Johnson & Johnson, and Novartis, are driving innovation through pipeline expansion, clinical trial programs, and strategic collaborations with hospitals, research institutions, and biotechnology companies. In addition, partnerships between pharmaceutical companies, academic research centers, and government-funded initiatives are accelerating access to cutting-edge biologics and fostering the development of combination therapies.
The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.
The biological therapies for cancer market has experienced rapid growth, driven by increasing adoption of targeted and immuno-oncology therapies across multiple tumor types. Rising demand for precision medicine is a key growth factor, as clinicians and healthcare systems prioritize treatments tailored to the molecular and immunological profile of individual patients. Advances in monoclonal antibodies, immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) are expanding the range of effective treatment options and enabling more durable clinical responses.
Major global players, including Merck & Co., Bristol-Myers Squibb, F. Hoffmann-La Roche, AstraZeneca, Johnson & Johnson, and Novartis, are driving innovation through pipeline expansion, clinical trial programs, and strategic collaborations with hospitals, research institutions, and biotechnology companies. In addition, partnerships between pharmaceutical companies, academic research centers, and government-funded initiatives are accelerating access to cutting-edge biologics and fostering the development of combination therapies.
Report Scope
This report provides an overview of the global biological therapies for the cancer market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024 and estimated data for the forecast period 2025 through 2030. The market is based on technology, application, end user, and region. The regions covered in this study include North America, Europe, Asia-Pacific, the Rest of the World, focusing on major countries in these regions.The report also sheds light on developments related to venture capital and corporate investments, regulatory trends, and the enterprise strategies of key firms as well as potential future opportunities stemming from biological therapies for cancer of precision medicine and population genomics programs. The combination of in-depth market forecasts, macroeconomic analysis, and tariff assessments makes this report a critical resource for stakeholders, investors, and policymakers seeking to understand and take advantage of the rapidly developing biological therapies for cancer sector. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It also analyzes emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the ranking/share of key players in the biological therapies for cancer market. It also has a dedicated section of company profiles that covers the details of key market players. For market estimates, data have been provided for 2022 and 2023 as the historic years, 2024 as the base year, and 2025-2030 for the forecast years.
The report includes:
- 43 data tables and 53 additional tables
- An analysis of the global markets for biological therapies for cancer treatment and related technologies
- Analyses of the global market trends, with revenue data for 2022-2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) through 2030
- Estimates of the current market size and revenue prospects for the global cancer biologics market, along with a market share analysis by product type, cancer type, and region
- Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, innovations and standards and the impacts of macroeconomic variables
- Impact analysis of the U.S. tariff laws on the market
- Insights derived from Porter’s Five Forces model, as well as global supply chain
- A look at major issues and trends related to the R&D of more effective cancer treatment, new cancer therapeutics in development and the outlook on cancer clinical trials
- Key marketed drugs and recent approvals, sales statistics and past performance of the top-selling biologics and insight into their patent expiries
- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including: Merck & Co. Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., AstraZeneca, and Johnson & Johnson
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologies and Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Cancer Clinical Trials and Biologics in Development
Chapter 8 Competitive Landscape
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- Amgen Inc.
- Astrazeneca
- Bayer AG
- Biontech SE
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- Gsk PLC
- Incyte
- Innate Pharma Inc.
- Johnson & Johnson
- Lilly Usa LLC
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 139 |
| Published | November 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 157 Billion |
| Forecasted Market Value ( USD | $ 225 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
